Novavax's COVID-19 vaccine could receive approval from Europe's drug regulator next week and subsequently an emergency use listing from the World Health Organization, the Financial Times reported on Thursday, sending shares of the U.S. drugmaker up 7%, Trend reports citing Reuters.
A WHO approval could come once the health body issued its own emergency use listing or if the EMA gave it a conditional marketing authorization, the newspaper reported, citing people familiar with the matter.
That could pave the way for the company and its partner, Serum Institute of India, to ship doses to the COVAX program, providing another vaccine to low-income countries.